<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38402887</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>403</Volume><Issue>10432</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>23</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to &lt;5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.</ArticleTitle><Pagination><StartPage>1164</StartPage><EndPage>1175</EndPage><MedlinePgn>1164-1175</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(23)02844-1</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(23)02844-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Novel oral poliovirus vaccine type 2 (nOPV2) has been engineered to improve the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence of circulating vaccine-derived polioviruses. This trial aimed to provide key safety and immunogenicity data required for nOPV2 licensure and WHO prequalification.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This phase 3 trial recruited infants aged 18 to &lt;52 weeks and young children aged 1 to &lt;5 years in The Gambia. Infants randomly assigned to receive one or two doses of one of three lots of nOPV2 or one lot of bivalent OPV (bOPV). Young children were randomised to receive two doses of nOPV2 lot 1 or bOPV. The primary immunogenicity objective was to assess lot-to-lot equivalence of the three nOPV2 lots based on one-dose type 2 poliovirus neutralising antibody seroconversion rates in infants. Equivalence was declared if the 95% CI for the three pairwise rate differences was within the -10% to 10% equivalence margin. Tolerability and safety were assessed based on the rates of solicited adverse events to 7 days, unsolicited adverse events to 28 days, and serious adverse events to 3 months post-dose. Stool poliovirus excretion was examined. The trial was registered as PACTR202010705577776 and is completed.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between February and October, 2021, 2345 infants and 600 young children were vaccinated. 2272 (96·9%) were eligible for inclusion in the post-dose one per-protocol population. Seroconversion rates ranged from 48·9% to 49·2% across the three lots. The minimum lower bound of the 95% CIs for the pairwise differences in seroconversion rates between lots was -5·8%. The maximum upper bound was 5·4%. Equivalence was therefore shown. Of those seronegative at baseline, 143 (85·6%) of 167 (95% CI 79·4-90·6) infants and 54 (83·1%) of 65 (71·7-91·2) young children seroconverted over the two-dose nOPV2 schedule. The post-two-dose seroprotection rates, including participants who were both seronegative and seropositive at baseline, were 604 (92·9%) of 650 (95% CI 90·7-94·8) in infants and 276 (95·5%) of 289 (92·4-97·6) in young children. No safety concerns were identified. 7 days post-dose one, 78 (41·7%) of 187 (95% CI 34·6-49·1) infants were excreting the type 2 poliovirus.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">nOPV2 was immunogenic and safe in infants and young children in The Gambia. The data support the licensure and WHO prequalification of nOPV2.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Bill &amp; Melinda Gates Foundation.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ochoge</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Futa</LastName><ForeName>Ahmed Cherno</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umesi</LastName><ForeName>Ama</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Affleck</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotei</LastName><ForeName>Larry</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daffeh</LastName><ForeName>Baboucarr</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saidy-Jah</LastName><ForeName>Ebrima</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Njie</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oyadiran</LastName><ForeName>Oluwafemi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edem</LastName><ForeName>Bassey</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jallow</LastName><ForeName>Musa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jallow</LastName><ForeName>Edrissa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donkor</LastName><ForeName>Simon A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tritama</LastName><ForeName>Erman</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Research and Development Division, PT Bio Farma, Bandung, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abid</LastName><ForeName>Talha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Kathryn A V</ForeName><Initials>KAV</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainou</LastName><ForeName>Bernardo A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konz</LastName><ForeName>John O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fix</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gast</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Ed</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia. Electronic address: ed.clarke@lshtm.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005714" MajorTopicYN="N" Type="Geographic">Gambia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests ET works for PT Biofarma who manufacture the novel oral poliovirus vaccine type 2 and the bivalent oral poliovirus vaccine used in this trial. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>25</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38402887</ArticleId><ArticleId IdType="pmc">PMC10985839</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(23)02844-1</ArticleId><ArticleId IdType="pii">S0140-6736(23)02844-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Polio Eradication Initiative  Polio today. https://polioeradication.org/polio-today/</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative  Polio eradication strategy 2022–2026: delivering on a promise. 2022. https://polioeradication.org/gpei-strategy-2022-2026/</Citation></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Global polio eradication initiative. Circulating vaccine-derived polioviruses, global update. August, 2020. https://polioeradication.org/wp-content/uploads/2020/12/20201118_cVDPV2_Global_Update_EN.pdf</Citation></Reference><Reference><Citation>Voorman A, Lyons H, Bennette C, et al. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2023;41(suppl 1):A85–A92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10973941</ArticleId><ArticleId IdType="pubmed">35339308</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative  Circulating vaccine-derived polioviruses. Sept 1, 2015. https://polioeradication.org/this-week/circulating-vaccine-derived-poliovirus/</Citation></Reference><Reference><Citation>Macklin GR, O'Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401–405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, Bujaki E, Dolan PT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736. 51.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I, Leroux-Roels I, Bandyopadhyay AS, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397:39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens X, Bandyopadhyay AS, Gast C, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397:27–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148–158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K, Bandyopadhyay AS, Hoque M, et al. Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. Lancet. 2023;401:131–139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9860215</ArticleId><ArticleId IdType="pubmed">36495882</ArticleId></ArticleIdList></Reference><Reference><Citation>Gast C, Bandyopadhyay AS, Sáez-Llorens X, et al. Fecal shedding of 2 novel live attenuated oral poliovirus type 2 vaccine candidates by healthy infants administered bivalent oral poliovirus vaccine/inactivated poliovirus vaccine: 2 randomized clinical trials. J Infect Dis. 2022;226:852–861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9470102</ArticleId><ArticleId IdType="pubmed">34610135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R, Mercer L, Gast C, et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines. 2022;7:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8837630</ArticleId><ArticleId IdType="pubmed">35149714</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  First ever vaccine listed under WHO emergency use. Nov 13, 2020. https://www.who.int/news/item/13-11-2020-first-ever-vaccine-listed-under-who-emergency-use</Citation></Reference><Reference><Citation>Precision Vaccinations  820 million novel polio vaccinations completed. Oct 29, 2023. https://www.precisionvaccinations.com/2023/10/29/820-million-novel-polio-vaccinations-completed</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol. 2016;1387:145–176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington C, Sun H, Jeffries-Miles S, et al. Culture-independent detection of poliovirus in stool samples by direct RNA extraction. Microbiol Spectr. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579935</ArticleId><ArticleId IdType="pubmed">34756088</ArticleId></ArticleIdList></Reference><Reference><Citation>Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–226.</Citation><ArticleIdList><ArticleId IdType="pubmed">4023479</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker EP, Ramani S, Lopman BA, et al. Causes of impaired oral vaccine efficacy in developing countries. Future Microbiol. 2018;13:97–118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7026772</ArticleId><ArticleId IdType="pubmed">29218997</ArticleId></ArticleIdList></Reference><Reference><Citation>Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis. 2001;33:531–541.</Citation><ArticleIdList><ArticleId IdType="pubmed">11462191</ArticleId></ArticleIdList></Reference><Reference><Citation>de Deus N, Capitine IPU, Bauhofer AFL, et al. Immunogenicity of reduced-dose monovalent type 2 oral poliovirus vaccine in Mocuba, Mozambique. J Infect Dis. 2022;226:292–298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400415</ArticleId><ArticleId IdType="pubmed">33180924</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy SB, Macklin GR, Mason Ross G, et al. Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey. Lancet Glob Health. 2023;11:e917–e923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10187988</ArticleId><ArticleId IdType="pubmed">37202026</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyenswah TG, Schue JL. Halting vaccine-derived poliovirus circulation: the novel type 2 oral vaccine might not be enough. Lancet Glob Health. 2023;11:e811–e812.</Citation><ArticleIdList><ArticleId IdType="pubmed">37202011</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13:926–939.</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Darwar R, Biya O, Greene SA, et al. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020. Vaccine. 2023;41(suppl 1):A25–A34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10354706</ArticleId><ArticleId IdType="pubmed">36863925</ArticleId></ArticleIdList></Reference><Reference><Citation>Konz JO, Schofield T, Carlyle S, et al. Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine. Vaccine X. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233139</ArticleId><ArticleId IdType="pubmed">34195600</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman A, Lyons H, Shuab F, et al. Evaluation of novel oral polio vaccine type 2 SIA impact in a large outbreak of circulating vaccine-derived poliovirus in Nigeria. J Infect Dis. 2023 doi: 10.1093/infdis/jiad222. published online June 26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad222</ArticleId><ArticleId IdType="pmc">PMC10938209</ArticleId><ArticleId IdType="pubmed">37357964</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper LV, Erberto TB, Danzomo AA, et al. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study. Lancet Infect Dis. 2024 doi: 10.1016/S1473-3099(23)00688-6. published online Jan 18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00688-6</ArticleId><ArticleId IdType="pubmed">38246190</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM. Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame. Lancet Glob Health. 2022;10:e1697–e1698.</Citation><ArticleIdList><ArticleId IdType="pubmed">36400075</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, Badizadegan K. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. Front Public Health. 2023;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10080024</ArticleId><ArticleId IdType="pubmed">37033033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashkenazi A, Melnick JL. Heterotypic antibody response after feeding of monovalent attenuated live poliovaccine. N Engl J Med. 1962;267:1228–1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">13965178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>